N-(2-氨基乙基)甲烷磺酰胺 | 83019-89-0

• 分子结构分类: 有机化合物 - 有机酸及其衍生物 - 有机磺酸及其衍生物
• 中文名称: N-(2-氨基乙基)甲烷磺酰胺
• 中文别名: 3-吗啉羧酸
• 英文名称: N-(2-aminoethyl)methanesulfonamide
• 英文别名: 2-(methanesulphonamido)ethylamine
• CAS: 83019-89-0
• 化学式: C₃H₁₀N₂O₂S
• mdl: MFCD04355317
• 分子量: 138.191
• InChiKey: GCDZDXVTDCMNMN-UHFFFAOYSA-N

物化性质

• 沸点：
  256.1±42.0 °C(Predicted)
• 密度：
  1.238±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  -1.6
• 重原子数：
  8
• 可旋转键数：
  3
• 环数：
  0.0
• sp3杂化的碳原子比例：
  1.0
• 拓扑面积：
  80.6
• 氢给体数：
  2
• 氢受体数：
  4

安全信息

• 危险等级：
  IRRITANT
• 海关编码：
  2935009090

SDS

Material Safety Data Sheet

---

Section 1. Identification of the substance
Product Name: N-(2-Aminoethyl)methanesulfonamide
Synonyms:

---

Section 2. Hazards identification
Harmful by inhalation, in contact with skin, and if swallowed.

---

Section 3. Composition/information on ingredients.
Ingredient name: N-(2-Aminoethyl)methanesulfonamide
CAS number: 83019-89-0

---

Section 4. First aid measures
Skin contact: Immediately wash skin with copious amounts of water for at least 15 minutes while removing
contaminated clothing and shoes. If irritation persists, seek medical attention.
Eye contact: Immediately wash skin with copious amounts of water for at least 15 minutes. Assure adequate
flushing of the eyes by separating the eyelids with fingers. If irritation persists, seek medical
attention.
Inhalation: Remove to fresh air. In severe cases or if symptoms persist, seek medical attention.
Ingestion: Wash out mouth with copious amounts of water for at least 15 minutes. Seek medical attention.

---

Section 5. Fire fighting measures
In the event of a fire involving this material, alone or in combination with other materials, use dry
powder or carbon dioxide extinguishers. Protective clothing and self-contained breathing apparatus
should be worn.

---

Section 6. Accidental release measures
Personal precautions: Wear suitable personal protective equipment which performs satisfactorily and meets local/state/national
standards.
Respiratory precaution: Wear approved mask/respirator
Hand precaution: Wear suitable gloves/gauntlets
Skin protection: Wear suitable protective clothing
Eye protection: Wear suitable eye protection
Methods for cleaning up: Mix with sand or similar inert absorbent material, sweep up and keep in a tightly closed container
for disposal. See section 12.
Environmental precautions: Do not allow material to enter drains or water courses.

---

Section 7. Handling and storage
Handling: This product should be handled only by, or under the close supervision of, those properly qualified
in the handling and use of potentially hazardous chemicals, who should take into account the fire,
health and chemical hazard data given on this sheet.
Store in closed vessels.
Storage:

---

Section 8. Exposure Controls / Personal protection
Engineering Controls: Use only in a chemical fume hood.
Personal protective equipment: Wear laboratory clothing, chemical-resistant gloves and safety goggles.
General hydiene measures: Wash thoroughly after handling. Wash contaminated clothing before reuse.

---

Section 9. Physical and chemical properties
Appearance: Not specified
Boiling point: No data
No data
Melting point:
Flash point: No data
Density: No data
Molecular formula: C3H10N2O2S
Molecular weight: 138.2

---

Section 10. Stability and reactivity
Conditions to avoid: Heat, flames and sparks.
Materials to avoid: Oxidizing agents.
Possible hazardous combustion products: Carbon monoxide, nitrogen oxides, sulfur oxides.

---

Section 11. Toxicological information
No data.

---

Section 12. Ecological information
No data.

---

Section 13. Disposal consideration
Arrange disposal as special waste, by licensed disposal company, in consultation with local waste
disposal authority, in accordance with national and regional regulations.

---

Section 14. Transportation information
Non-harzardous for air and ground transportation.

---

Section 15. Regulatory information
No chemicals in this material are subject to the reporting requirements of SARA Title III, Section
302, or have known CAS numbers that exceed the threshold reporting levels established by SARA
Title III, Section 313.

---

SECTION 16 - ADDITIONAL INFORMATION
N/A

反应信息

• 作为反应物：
  描述：

  N-(2-氨基乙基)甲烷磺酰胺 在 N,N'-羰基二咪唑 作用下， 以 N,N-二甲基甲酰胺 为溶剂， 反应 3.0h， 生成 2-methylsulfanyl-6-o-tolyl-pyrido[2,2-d]pyrimidine-7-carboxylic acid (2-methanesulfonylamino-ethyl)-amide
  参考文献：
  名称：

  [EN] 6-(2-ALKYL-PHENYL) - PYRIDO[2,3-D] PYRIMIDINES USEFUL AS PROTEINE KINASE INHIBITORS
  [FR] 6-(2-ALKYL-PHÉNYL)-PYRIDO[2,3-D]PYRIMIDINES UTILES COMME INHIBITEURS DE LA PROTÉINE KINASE

  摘要：

  本发明的对象是公式(I)的化合物、它们的药用可接受盐、对映异构体、非对映异构体和外消旋混合物，上述化合物的制备、含有它们的药物及其制造，以及上述化合物在控制或预防诸如癌症等疾病方面的用途。

  公开号：

  WO2006032452A1
• 作为产物：
  描述：

  tert-butyl (2-(methylsulfonamido)ethyl)carbamate 在 盐酸 作用下， 以 1,4-二氧六环 为溶剂， 以100%的产率得到N-(2-氨基乙基)甲烷磺酰胺
  参考文献：
  名称：

  [EN] NEW THIADIAZOLE DERIVATIVES
  [FR] NOUVEAUX DÉRIVÉS DE THIADIAZOLE

  摘要：

  本发明涉及式(I)的噻二唑衍生物，其制备过程以及包含它们的药物组合物。这些化合物是S1P1受体的强激动剂，因此它们可用于治疗、预防或抑制那些已知可通过激动鞘氨醇-1-磷酸受体（S1P1）得到改善的疾病和失调，例如自身免疫性疾病、慢性免疫和炎症性疾病、移植排斥反应、恶性肿瘤、与血管生成相关的失调、疼痛、神经疾病、病毒性和传染性疾病。

  公开号：

  WO2011035900A1

文献信息

• Chemoselective Conjugate Reduction of α,β-Unsaturated Ketones Catalyzed by Rhodium Amido Complexes in Aqueous Media
  作者：Xuefeng Li、Liangchun Li、Yuanfu Tang、Ling Zhong、Linfeng Cun、Jin Zhu、Jian Liao、Jingen Deng

  DOI：10.1021/jo100256t

  日期：2010.5.7

  electron-withdrawing functional groups, could be reduced on the alkenic double bonds with high selectivities employing amido-rhodium hydride complex in aqueous media, and up to 100% chemoselectivity has been achieved. It is notable that the chemoselectivity was improved significantly on going from organic solvent to water. Moreover, a 1,4-addition mechanism has been proposed on the basis of the corresponding

  尽管Noyori Ru-TsDPEN配合物的显着特征是转移氢化反应对C═O官能团具有高度的化学选择性并且对烯烃具有耐受性，但我们的早期报告表明，化学选择性可以从C═O切换为C═C键在活化的α，β-不饱和酮的转移氢化中。现在我们发现，即使在没有其他吸电子官能团的情况下，也可以在水性介质中使用酰胺-铑氢化物络合物以高选择性将各种α，β-不饱和酮还原成烯烃双键，并且具有很高的选择性。已经实现了化学选择性。值得注意的是，从有机溶剂到水，化学选择性显着提高。此外，1
• 三唑并吡啶类化合物及其制备方法和用途
  申请人：沈阳药科大学

  公开号：CN109897036B

  公开（公告）日：2021-07-30

  本发明属于医药技术领域，涉及三唑并吡啶类化合物及其制备方法和用途。具体涉及具有通式Ⅰ结构的三唑并吡啶类化合物及其立体异构体以及药学上可接受的盐，其中R1、R2、R3、R4如权利要求和说明书所述。本发明所述的化合物及其立体异构体以及药学上可接受的盐和含有该化合物的组合物均对PD‑1/PD‑L1蛋白/蛋白相互作用具有显著抑制作用，能够治疗癌症、病毒感染等多种疾病，因此，可用于制备预防和/或治疗与PD‑1/PD‑L1信号通路有关的疾病的药物。
• New thiadiazole derivatives
  申请人：Almirall, S.A.

  公开号：EP2305660A1

  公开（公告）日：2011-04-06

  The present invention relates to thiadiazole derivatives of formula (I), to processes for their preparation and to pharmaceutical compositions containing them. These compounds are potent agonists of S1P1 receptors and thus, they are useful in the treatment, prevention or suppression of diseases and disorders known to be susceptible to improvement by sphingosine-1-phosphate receptors agonists (S1P1), such as autoimmune diseases, chronic immune and inflammatory diseases, transplant rejection, malignant neoplastic diseases, angiogenic-related disorders, pain, neurological diseases, viral and infectious diseases.

  本发明涉及式(I)的噻二唑衍生物，它们的制备过程以及包含它们的药物组合物。这些化合物是S1P1受体的强激动剂，因此，它们可用于治疗、预防或抑制那些已知可通过鞘氨醇-1-磷酸受体激动剂（S1P1）改善的疾病和失调，例如自身免疫性疾病、慢性免疫和炎症性疾病、移植排斥反应、恶性肿瘤疾病、与血管生成相关的失调、疼痛、神经系统疾病、病毒和感染性疾病。
• [EN] NOVEL DICHLORO-PHENYL-PYRIDO [2,3-D] PYRIMIDINE DERIVATES, THEIR MANUFACTURE AND USE AS PHARMACEUTICAL AGENTS<br/>[FR] DERIVES DE DICHLORO-PHENYL-PYRIDO [2,3-D] PYRIMIDINE, FABRICATION DE CEUX-CI ET UTILISATION DE CEUX-CI COMME AGENTS PHARMACEUTIQUES
  申请人：HOFFMANN LA ROCHE

  公开号：WO2005090344A1

  公开（公告）日：2005-09-29

  The invention describes compounds of the general formula (I), a process for their manufacture, medicaments containing them and their manufacture as well as the use of these compounds as pharmaceutically active agents. The said compounds show activity as protein kinase inhibitors, in particular src family tyrosine kinase inhibitors, and may therefore be useful for the treatment of diseases mediated by said tyrosine kinases.

  本发明描述了通式(I)的化合物、它们的制造工艺、含有它们的药物及其制造方法，以及这些化合物作为药物活性剂的使用。所述化合物作为蛋白激酶抑制剂，特别是src家族酪氨酸激酶抑制剂，显示出活性，因此可能用于治疗由所述酪氨酸激酶介导的疾病。
• Discovery of [1,2,4]Triazolo[4,3-<i>a</i>]pyridines as Potent Inhibitors Targeting the Programmed Cell Death-1/Programmed Cell Death-Ligand 1 Interaction
  作者：Mingze Qin、Qi Cao、Shuaishuai Zheng、Ye Tian、Haotian Zhang、Jun Xie、Hongbo Xie、Yajing Liu、Yanfang Zhao、Ping Gong

  DOI：10.1021/acs.jmedchem.9b00312

  日期：2019.5.9

  Inhibition of the programmed cell death-1 (PD-1)/programmed cell death-ligand 1 (PD-L1) interaction using small-molecule inhibitors is an emerging immunotherapeutic approach. A novel series of [1,2,4]triazolo[4,3- a]pyridines were designed and found to be potent inhibitors of the PD-1/PD-L1 interaction. Among them, compound A22 exhibited the most potent activity, as assessed by homogenous time-resolved

  使用小分子抑制剂抑制程序性细胞死亡1（PD-1）/程序性细胞死亡配体1（PD-L1）相互作用是一种新兴的免疫治疗方法。设计了一系列新的[1,2,4]三唑并[4,3-a]吡啶，并发现它们是PD-1 / PD-L1相互作用的有效抑制剂。其中，通过均相时间分辨荧光分析评估，化合物A22表现出最强的活性，IC50为92.3 nM。此外，在Hep3B / OS-8 / hPD-L1和CD3 T细胞的共培养模型中，A22剂量依赖性升高的干扰素-γ产生。我们得出的结论是，A22是开发PD-1 / PD-L1相互作用抑制剂的有前途的先导化合物。此外，我们探索了新合成的[1,2,4] triazolo [4，并证明了环融合策略可用于设计Bristol-Myers Squibb化学系列的类似物。这些研究为将来的药物设计铺平了道路。